Everest Medicines and Shanghai Pharmaceuticals Deepen Partnership for Drug Distribution in China
China-based Everest Medicines (HKG: 1952) has announced a strategic partnership with Shanghai Pharmaceuticals marking a...
HKG: 1952
Everest Medicines Completes Enrollment for Nefecon’s Phase III Extension Study in China
China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China...
Everest Medicines Launches Xerava Antibiotic in China, Marking Commercial Milestone
Everest Medicines (HKG: 1952) has announced the commercial launch of its Xerava (eravacycline) antibiotic in...
Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration
China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU)...
Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer to Drive Innovation
China-based Everest Medicines (HKG: 1952) has announced the appointment of Dr. Mike Berry as Chief...
Everest Medicines Completes Patient Enrollment in Etrasimod Phase III UC Trial
Everest Medicines (HKG: 1952), a China-based biopharmaceutical company, has declared the successful completion of patient...
Everest Medicines’ Nefecon for IgAN Approved for Clinical Use in Hainan
China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for...
Everest Medicines and SPH Keyuan Ink MoU to Expand Xerava Distribution in China
China-based Everest Medicines (HKG: 1952) has announced a Memorandum of Understanding (MoU) with a subsidiary...
Everest Medicines’ Nefecon NDA Accepted for Review by Singapore’s HSA
China-based Everest Medicines (HKG: 1952) has announced that the Health Sciences Authority (HSA) of Singapore...
Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates
China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key...
Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront...
Everest Medicines Receives $280 Million from Gilead Sciences for Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced that it has received a full upfront payment...
Everest Medicines Partners with Guangdong Provincial People’s Hospital in Kidney Disease Research
China-based Everest Medicines Ltd (HKG: 1952) has announced a comprehensive strategic partnership with Guangdong Provincial...
Everest Medicines’ Xerava Receives NMPA Approval for Complicated Intra-Abdominal Infections
China-based Everest Medicines Limited (HKG: 1952) has announced that it has received market approval from...
Everest Medicines’ Nefecon Included in South Korea’s GIFT Program
China-based Everest Medicines (HKG: 1952) has announced that South Korea’s Ministry of Food and Drug...
Everest Medicines’ EVER206 Shows Positive Phase I Results in China
China-based Everest Medicines (HKG: 1952) has announced top-line results from a Phase I study in...
Everest Medicines Outlines Strategic Plans for Expansion and Growth
China – based biopharmaceutical company Everest Medicines (HKG: 1952) has announced its strategic plans for...
Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE
China-based Everest Medicines (HKG: 1952) has announced that the Center for Drug Evaluation (CDE) of...
Everest Medicines Launches First Phase of Global mRNA Vaccine Manufacturing Site
China-based Everest Medicines (HKG: 1952) has announced the initiation of the operation of the first...
Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine
China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept...